Equities researchers at Instinet began coverage on shares of Solid Biosciences (NASDAQ:SLDB) in a research note issued on Tuesday. The brokerage set a “buy” rating and a $52.00 price target on the stock. Instinet’s price objective would indicate a potential upside of 108.58% from the stock’s current price.
Several other equities analysts have also recently weighed in on the company. Leerink Swann assumed coverage on Solid Biosciences in a report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on Solid Biosciences in a report on Tuesday. They issued a “neutral” rating for the company. Finally, Goldman Sachs Group assumed coverage on Solid Biosciences in a report on Tuesday. They issued a “neutral” rating for the company.
Solid Biosciences (NASDAQ SLDB) opened at $24.93 on Tuesday. Solid Biosciences has a fifty-two week low of $19.12 and a fifty-two week high of $29.25.
In other Solid Biosciences news, Director Life Sciences Maste Perceptive purchased 1,020,000 shares of the stock in a transaction dated Tuesday, January 30th. The stock was bought at an average price of $16.22 per share, with a total value of $16,544,400.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
WARNING: This piece was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/02/20/solid-biosciences-sldb-receives-new-coverage-from-analysts-at-instinet.html.
About Solid Biosciences
Solid Biosciences, LLC is a life science company. The Company focuses on developing therapies for Duchenne muscular dystrophy (DMD). It is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.